Guidelines for time-to-event end point definitions in breast cancer trials: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). [Ann Oncol, 26, (2015), 873-879] doi: 10.1093/annonc/mdv106

S. Gourgou-Bourgade, D. Cameron, P. Poortmans, B. Asselain, D. Azria, F. Cardoso, R. A'Hern, J. Bliss, J. Bogaerts, H. Bonnefoi, E. Brain, M. J. Cardoso, B. Chibaudel, R. Coleman, T. Cufer, L. Dal Lago, F. Dalenc, E. De Azambuja, M. Debled, S. DelalogeT. Filleron, J. Gligorov, M. Gutowski, W. Jacot, C. Kirkove, G. MacGrogan, S. Michiels, I. Negreiros, B. V. Offersen, F. Penault Llorca, G. Pruneri, H. Roche, N. S. Russell, F. Schmitt, V. Servent, B. Thürlimann, M. Untch, J. A. van der Hage, G. van Tienhoven, H. Wildiers, J. Yarnold, F. Bonnetain, S. Mathoulin-Pélissier, C. Bellera, T. S. Dabakuyo-Yonli

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)2505
Number of pages1
JournalAnnals of Oncology
Issue number12
Publication statusPublished - Dec 1 2015

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this